Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Mu-opioid receptor agonists
Noroxymorphone
Другие языки:

    Noroxymorphone

    Подписчиков: 0, рейтинг: 0
    Noroxymorphone
    Noroxymorphone.svg
    Clinical data
    Routes of
    administration    		 intravenous, intramusucular, subcutaneous, oral, rectal, intranasal
    Legal status
    Legal status
    Identifiers
    • 7,8-Dihydro-14-hydroxynormorphinone
    CAS Number
    PubChem CID
    DrugBank
    ChemSpider
    UNII
    CompTox Dashboard (EPA)
    ECHA InfoCard 100.046.859
    Chemical and physical data
    Formula C16H17NO4
    Molar mass 287.315 g·mol−1
    3D model (JSmol)
    • Oc1ccc2C[C@H]3NCC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O
    • InChI=1S/C16H17NO4/c18-9-2-1-8-7-11-16(20)4-3-10(19)14-15(16,5-6-17-11)12(8)13(9)21-14/h1-2,11,14,17-18,20H,3-7H2/t11-,14+,15+,16-/m1/s1
    • Key:HLMSIZPQBSYUNL-IPOQPSJVSA-N

    Noroxymorphone is an opioid which is both a metabolite of oxymorphone and oxycodone and is manufactured specifically as an intermediate in the production of narcotic antagonists such as naltrexone and others. It is a potent agonist of the μ-opioid receptor, but is poorly able to cross the blood-brain-barrier into the central nervous system, and for this reason, has only minimal analgesic activity.

    In the United States, noroxymorphone is controlled as a Schedule II Narcotic controlled substance with an ACSCN of 9637 and in 2014 the DEA set annual aggregate manufacturing quotas of 17 500 kilogrammes for conversion and 1262.5 kg for sale. In other countries, it may be similarly controlled, controlled at a lower level, or regulated in another way.

    See also


    Новое сообщение